title: Review of tocilizumab in the treatment of rheumatoid arthritis.
abstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is a humanized anti-human IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptor, and at detectable levels in blood, tocilizumab is capable of almost completely blocking the transmembrane signaling of IL-6. In clinical trials for patients with RA in Japan, tocilizumab monotherapy has shown clinical efficacy equaling that of tumor necrosis factor (TNF) inhibitor in combination with methotrexate, and in an extension study in patients who responded to tocilizumab, almost no patients showed a decrease in the efficacy of tocilizumab. Evidence obtained in a phase III study in Japan demonstrated that tocilizumab monotherapy had a sig-nificant inhibitory effect on the progression of structural joint damage compared with that of conventional disease modifying antirheumatic drugs (DMARDs). Furthermore it has been shown that tocilizumab has an excellent ability to suppress serum amyloid A levels and could therefore be an important therapeutic strategy in amyloid A amyloidosis secondary to rheumatic diseases. The safety profile of tocilizumab appears to be satisfactory. However, several serious infections were also reported, and careful monitoring is therefore important during use.
authors.affiliation: Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, Japan.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Okuda
references.citation: J Rheumatol. 2003 Jul;30(7):1426-35
references.pmid: 12858437
references.citation: Clin Exp Immunol. 1998 Jun;112(3):397-402
references.pmid: 9649207
references.citation: J Rheumatol. 2006 May;33(5):921-3
references.pmid: 16541480
references.citation: Arthritis Rheum. 2002 Dec;46(12):3143-50
references.pmid: 12483717
references.citation: Arthritis Rheum. 2006 Sep;54(9):2817-29
references.pmid: 16947782
references.citation: Biochem Biophys Res Commun. 2004 Feb 6;314(2):363-9
references.pmid: 14733913
references.citation: Ann Rheum Dis. 2009 Oct;68(10):1580-4
references.pmid: 19019888
references.citation: Arthritis Rheum. 2003 Jun;48(6):1521-9
references.pmid: 12794819
references.citation: Rheumatology (Oxford). 2001 May;40(5):544-51
references.pmid: 11371663
references.citation: Ann Rheum Dis. 2006 Dec;65(12):1667-9
references.pmid: 17105857
references.citation: J Immunol. 1982 Mar;128(3):1296-301
references.pmid: 6799573
references.citation: Arthritis Rheum. 2004 Feb;50(2):650-9
references.pmid: 14872510
references.citation: J Biol Chem. 1994 Sep 16;269(37):23286-9
references.pmid: 8083235
references.citation: J Immunol. 2002 May 1;168(9):4620-7
references.pmid: 11971010
references.citation: Arthritis Rheum. 2006 Sep;54(9):2997-3000
references.pmid: 16947531
references.citation: J Bone Miner Res. 1996 Jan;11(1):88-95
references.pmid: 8770701
references.citation: Ann Rheum Dis. 2007 Sep;66(9):1162-7
references.pmid: 17485422
references.citation: Am J Cardiol. 2006 Jul 1;98(1):14-8
references.pmid: 16784912
references.citation: Nature. 1986 Nov 6-12;324(6092):73-6
references.pmid: 3491322
references.citation: Arthritis Rheum. 2005 Jul;52(7):2212-21
references.pmid: 15986351
references.citation: Arthritis Rheum. 2004 Jun;50(6):1761-9
references.pmid: 15188351
references.citation: Genes Cells. 2005 Nov;10(11):1051-63
references.pmid: 16236134